CHINESE APPROVAL

AstraZeneca's drug Tagrisso gets China nod for early lung cancer treatment

China's National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said.